Biotech Values

[DewDiligence]

BIIB/NVS/SNY/MNTA—It’s looking increasingly likely that Tecfidera will end up with more market share than Gilenia—probably more than the combined share of the other oral MS meds.

It’s notable that Tecfidera appears to be increasing the total number of patients on MS meds, rather than merely stealing market share from other drugs.

As a MNTA shareholder, I’m especially interested in Copaxone’s US market share, which is currently about 40%. If a substantial portion of Tecifdera’s sales come from new patients rather than switches, Copaxone could continue to hold a large market share of the US market—probably at least 30%—for several years to come.